Azithromycin in the management of Chlamydia trachomatis infections. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Azithromycin in the management of Chlamydia trachomatis infections.

Int J STD AIDS. 1996;7 Suppl 1:5-8. Unique Identifier : AIDSLINE MED/96230312
Ridgway GL; Department of Clinical Microbiology, University College London; Hospitals, UK.

Abstract: The unique pharmacological profile of the azalide macrolide azithromycin, coupled with its in vitro activity against both Chlamydia trachomatis and the ureaplasmas, suggested that genital infections caused by these bacteria could be successfully treated with a single dose of the antibiotic. This has now been confirmed in worldwide clinical studies. A single oral dose of azithromycin 1 g eradicates C. trachomatis in almost 100% of cases of non-gonococcal urethritis and cervicitis. Unfortunately, there are no specific clinical signs for genital chlamydial infection. It is therefore necessary to use therapy effective against known and unknown pathogens for treating lower genital tract infection. Clinical cure rates for both chlamydial and non-chlamydial, non-gonococcal infections compare favourably with standard 7-day doxycycline therapy, being in excess of 85%. Side effects are few (< 20%) and essentially minor.
Keywords: Antibiotics, Macrolide/*THERAPEUTIC USE Azithromycin/*THERAPEUTIC USE Cervicitis/DRUG THERAPY *Chlamydia trachomatis Chlamydia Infections/*DRUG THERAPY Clinical Trials Female Human Male Urethritis/DRUG THERAPY JOURNAL ARTICLEKWDantibiotics,macrolide/KWDtherapeuticuseazithromycin/KWDtherapeuticusecervicitis/drugtherapyKWDchlamydiatrachomatischlamydiainfections/KWDdrugtherapyclinicaltrialsfemalehumanmaleurethritis/drugtherapyjournalarticle
961030
M96A1418

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .